CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Danish biotech firm Genmab's nine-month revenue up on higher royalties and product sales

By Reuters News


Overview

  • Denmark biotech firm's nine-month revenue rose 22% yr/yr, driven by higher royalties and product sales

  • Adjusted operating profit for nine months grew, reflecting investment in pipeline and commercialization

  • Company cites recent approvals and positive late-stage trial results for key oncology assets


Outlook

  • Genmab is maintaining its 2026 financial guidance published August 6, 2026


Result Drivers

  • ROYALTY REVENUE - Higher royalties from DARZALEX and Kesimpta drove revenue growth

  • PRODUCT SALES - Increased EPKINLY/TEPKINLY net product sales contributed to revenue rise

  • PIPELINE INVESTMENT - Higher operating expenses mainly reflected investment in product pipeline and commercialization capabilities


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Operating Expenses

$2.02 bln

9M Operating Profit

$986 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and 3 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Genmab A/S is DKK4,050.00, about 13.2% above its November 4 closing price of DKK3,578.00

  • The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 20 three months ago


Reuters Recommended Reads

  • Nov 4 - Novo Nordisk Q3 adjusted profit, sales jump on GLP-1 demand; raises outlook

  • Nov 4 - Royalty Pharma Q3 adjusted EBITDA beats estimates; raises 2026 guidance

  • Nov 3 - Amgen Q3 revenue beats expectations on higher volumes


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.